Sponsor or institution
Clinical trials and research at Vyriad, Inc.
As of November 12, 2026, Find a Trial lists 1 clinical trial run by Vyriad, Inc. that is recruiting, in United States. By phase: Phase 1 (1). There are also 1 NIH-funded research project at this institution, with $1.0 million in listed awards. Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 1Clinical trials
- 1NIH research projects
- 1Country
All recruiting trials (1)
-
In Vivo BCMA-CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma
This study tests VV169, a one-time in vivo CAR-T treatment, in adults with multiple myeloma that has come back or not responded to standard therapy.
NIH-funded research (1)
Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.
-
In vivo BCMA-CAR T therapy delivered by a single IV treatment for multiple myeloma
A new therapy aims to generate CAR-T cells directly inside the patient’s body to treat multiple myeloma, potentially reducing wait times and procedure costs.
Quick answers
How many clinical trials run by Vyriad, Inc. are recruiting right now?
1, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in United States. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.